Dr Kerry Rogers: Ibrutinib's Impact on Vaccine Response

Ibrutinib has the potential to improve vaccine response for patients with chronic lymphocytic leukemia, and an ongoing trial will help provide a better understanding, explained Kerry Rogers, MD, assistant professor, internal medicine, Division of Hematology, The Ohio State University Comprehensive Cancer Center.

Transcript

How does vaccination influence response of patients with chronic lymphocytic leukemia to ibrutinib?

Ibrutinib is an immune-modulatory agent, so it has the potential to improve vaccine responses. However, we don't have enough data that's looking at this yet to have a firm conclusion as to how ibrutinib affects this. We have an ongoing studio that looks at vaccinating people and then treating them with ibrutinib or treating them with ibrutinib and treating them with vaccines that will answer the question as to whether or not ibrutinib can boost vaccine responses. We suspect, based on its immunologic actions, that it might, but that is something that we'll have to see.